Stuart Grieve

I've spent a decade progressing at Teva Pharmaceuticals, leading product launches and innovation partnerships across the UK healthcare ecosystem. Most recently, I developed the go-to-market strategy for a denosumab biosimilar that became the leading product, generating £740,000 in sales within four months.

I re-established the £5 million-per-year varenicline smoking-cessation market, helping more than 12,000 people quit smoking since 2025. By leading cross-functional teams, working with ICBs and local authorities on PGDs, and coordinating marketing agencies, I helped achieve more than 60% market share for over two years.

I've also launched four branded generic medicines valued at £9 million for 2026, led a £450,000 personalised-medicine pilot with Closed Loop Medicine, and established new launch processes with automated cross-functional task management.

I work at the intersection of commercial launches, price management, NHS pathway integration, and strategic partnerships. I'm currently completing a Senior Leadership MBA while continuing to build scalable growth for patients, healthcare professionals, and Teva.